|
CA2531684C
(en)
|
2003-07-22 |
2014-03-11 |
Crucell Holland B.V. |
Binding molecules against sars-coronavirus and uses thereof
|
|
CA2548942C
(en)
|
2003-12-05 |
2013-10-15 |
Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health |
Anti-sars monoclonal antibodies
|
|
EP1812067B1
(en)
|
2004-11-11 |
2012-03-21 |
Crucell Holland B.V. |
Compositions against sars-coronavirus and uses thereof
|
|
DK1817340T3
(da)
|
2004-11-12 |
2012-08-13 |
Xencor Inc |
Fc-varianter med ændret binding til fcrn
|
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
RU2529951C2
(ru)
|
2007-12-26 |
2014-10-10 |
Ксенкор, Инк. |
ВАРИАНТЫ Fc С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ C FcRn
|
|
PT3031913T
(pt)
|
2013-08-09 |
2019-05-31 |
Astellas Pharma Inc |
Novo anticorpo anti-receptor de tslp humana
|
|
CA2962731A1
(en)
|
2014-10-01 |
2016-04-07 |
Medimmune Limited |
Binding proteins specific for lox1 and uses thereof
|
|
CR20180365A
(es)
|
2015-12-16 |
2018-09-28 |
Amgen Inc |
PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
|
|
JP7695698B2
(ja)
|
2019-01-14 |
2025-06-19 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
細胞内部移行をモジュレートするための組成物および方法
|
|
AR120698A1
(es)
|
2019-12-09 |
2022-03-09 |
Ablynx Nv |
Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
|
|
JP2023512684A
(ja)
|
2020-02-03 |
2023-03-28 |
ヴィア・バイオテクノロジー・インコーポレイテッド |
Ｓａｒｓ－ｃｏｖ－２に対する抗体およびそれを使用する方法
|
|
WO2021156490A2
(en)
*
|
2020-02-06 |
2021-08-12 |
Vib Vzw |
Corona virus binders
|
|
SG11202110145SA
(en)
|
2020-02-26 |
2021-10-28 |
Vir Biotechnology Inc |
Antibodies against sars-cov-2 and methods of using the same
|
|
CN115515976A
(zh)
|
2020-03-19 |
2022-12-23 |
帝国理工学院创新有限公司 |
冠状病毒抗体
|
|
US11028167B1
(en)
|
2020-03-23 |
2021-06-08 |
Centivax, Inc. |
Anti-SARS-Cov-2 antibodies derived from 3bgf
|
|
CR20220552A
(es)
|
2020-04-02 |
2023-01-17 |
Regeneron Pharma |
Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
|
|
WO2021203053A1
(en)
|
2020-04-03 |
2021-10-07 |
Vir Biotechnology, Inc. |
Immunotherapy targeting a conserved region in sars coronaviruses
|
|
US20230348571A1
(en)
|
2020-04-06 |
2023-11-02 |
Vanderbilt University |
Cross-reactive coronavirus antibodies and uses thereof
|
|
TW202204397A
(zh)
|
2020-04-10 |
2022-02-01 |
美商亞得捷歐治療公司 |
對冠狀病毒s蛋白質具特異性之化合物及其用途
|
|
JP2023523549A
(ja)
|
2020-04-14 |
2023-06-06 |
ヴィア・バイオテクノロジー・インコーポレイテッド |
ＳＡＲＳ－ＣｏＶ－２に対する抗体およびそれを使用する方法
|
|
CN115461364B
(zh)
|
2020-04-28 |
2025-12-16 |
北京大学 |
一种抗新型冠状病毒的单克隆抗体及其应用
|
|
MX2022013886A
(es)
|
2020-05-08 |
2022-11-30 |
Vir Biotechnology Inc |
Anticuerpos contra coronavirus de tipo 2 causante del sindrome respiratorio agudo severo (sars-cov-2).
|
|
WO2021247925A1
(en)
|
2020-06-03 |
2021-12-09 |
Vir Biotechnology, Inc. |
Structure-guided immunotherapy against sars-cov-2
|
|
CA3183367A1
(en)
|
2020-07-06 |
2022-01-13 |
Gevorg GRIGORYAN |
Antigen binding molecules targeting sars-cov-2
|
|
IL299631A
(en)
|
2020-07-06 |
2023-03-01 |
Flagship Pioneering Innovations Vi Llc |
Antigen binding molecules targeting sars-cov-2
|
|
WO2022015573A2
(en)
|
2020-07-13 |
2022-01-20 |
President And Fellows Of Harvard College |
Sars-cov-2 antigen-binding proteins and uses thereof
|
|
EP4188951A4
(en)
|
2020-07-27 |
2024-08-28 |
IGM Biosciences, Inc. |
Multimeric coronavirus binding molecules and uses thereof
|
|
WO2022046888A1
(en)
|
2020-08-25 |
2022-03-03 |
Target Discovery Merger Sub II, LLC |
Sars-cov-2 associated antibody compositions and methods of use
|
|
KR20230058434A
(ko)
|
2020-08-26 |
2023-05-03 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
SARS-CoV-2를 표적으로 하는 항원 결합 분자
|
|
JP2024502046A
(ja)
|
2020-12-29 |
2024-01-17 |
バル－チャム，リミティド パートナーシップ |
Ｃｏｖｉｄ－１９に対する中和モノクローナル抗体
|
|
WO2022159685A2
(en)
|
2021-01-22 |
2022-07-28 |
Vanderbilt University |
Sars-cov-2 coronavirus antibodies and uses thereof
|
|
WO2022204202A1
(en)
|
2021-03-23 |
2022-09-29 |
Vir Biotechnology, Inc. |
Antibodies that bind to multiple sarbecoviruses
|
|
CA3218489A1
(en)
|
2021-05-24 |
2022-12-01 |
Vir Biotechnology, Inc. |
Engineered polypeptides
|
|
US20240270797A1
(en)
|
2021-06-23 |
2024-08-15 |
Cz Biohub Sf, Llc |
Coronavirus neutralizing compositions and associated methods
|
|
TW202315895A
(zh)
|
2021-08-27 |
2023-04-16 |
瑞士商休曼生物醫藥股份公司 |
經工程化的組成物
|
|
EP4147716A1
(en)
|
2021-09-10 |
2023-03-15 |
Samatva Research Corporation |
Anti-virus moiety immobilised in a matrix
|
|
AU2023265164A1
(en)
|
2022-05-06 |
2024-11-21 |
Generate Biomedicines, Inc. |
Antigen binding molecules targeting sars-cov-2
|